AC Immune Announces Appointment of Dr. Marie Kosco-Vilbois as Chief Scientific Officer
03 January 2019 - 8:00PM
Lausanne, Switzerland, January 3, 2019 -
AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage
biopharmaceutical company with a broad pipeline focused on
Neurodegenerative Diseases, today announced that it has appointed
Dr. Marie Kosco-Vilbois, as Chief Scientific Officer, effective
January 3, 2019.
Prof. Andrea Pfeifer, CEO of AC Immune SA,
commented: "I am delighted to welcome Dr. Marie Kosco-Vilbois
as our Chief Scientific Officer. The Company will benefit greatly
from her extensive experience in Immunology and Drug Development,
which will enhance growth of the Company's robust pipeline in
Neurodegenerative Diseases."
In this position, Dr. Kosco-Vilbois will report
directly to CEO Andrea Pfeifer. To facilitate her rapid integration
into the Company she will be supported by Dr. David Lowe who has
led AC Immune's Research ad interim and has held senior R&D
roles in the Company since 2014.
About Dr. Marie Kosco-Vilbois Dr.
Kosco-Vilbois, a US citizen, has extensive experience in the
biopharmaceutical industry and has served as Chief Scientific
Officer of Novimmune since 2005. Prior to joining Novimmune in
2002, Dr. Kosco-Vilbois was Head of Immunology and Preclinical
Pharmacology at the Serono Pharmaceutical Research Institute, a
Senior Scientist and then Head of Immunology at the Glaxo Wellcome
Research Institute in Geneva and a Scientific Member of the Basel
Institute for Immunology. During her career, she has taken numerous
Biologicals from discovery into pre-clinical studies and clinical
development, most notably filing market applications of a
Biological for an Orphan indication.Dr. Kosco-Vilbois gained her
Bachelor's Degree in Biology from Rutgers University, New Jersey,
US, and a PhD in Anatomy and Immunology from the Medical College of
Virginia/Virginia Commonwealth University School of Medicine,
US.
About AC Immune SAAC Immune SA is a
clinical-stage Swiss-based biopharmaceutical company, listed on
NASDAQ, which aims to become a global leader in precision medicine
for Neurodegenerative Diseases. The Company designs, discovers and
develops therapeutic as well as diagnostic products intended to
prevent and modify diseases caused by misfolding proteins. AC
Immune's two proprietary technology platforms create antibodies,
small molecules and vaccines designed to address a broad spectrum
of neurodegenerative indications, such as Alzheimer's disease (AD).
The Company's pipeline features nine therapeutic and three
diagnostic product candidates - with five product candidates
currently in clinical trials. The most advanced of these is
crenezumab, a humanized anti-beta-amyloid monoclonal IgG4 antibody
that targets monomeric and aggregated forms of beta-amyloid, with
highest affinity for neurotoxic oligomers. Crenezumab is currently
in two Phase 3 clinical studies for AD, under a global program
conducted by collaboration partner Roche/Genentech. Other
collaborations include Lilly, Biogen, Janssen Pharmaceuticals,
Nestlé Institute of Health Sciences, Life Molecular Imaging
(formerly Piramal Imaging) and Essex Bio-Technology.
Forward looking statementsThis press release contains
statements that constitute "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934. Forward-looking
statements are statements other than historical fact and may
include statements that address future operating, financial or
business performance or AC Immune's strategies or expectations. In
some cases, you can identify these statements by forward-looking
words such as "may," "might," "will," "should," "expects," "plans,"
"anticipates," "believes," "estimates," "predicts," "projects,"
"potential," "outlook" or "continue," and other comparable
terminology. Forward-looking statements are based on management's
current expectations and beliefs and involve significant risks and
uncertainties that could cause actual results, developments and
business decisions to differ materially from those contemplated by
these statements. These risks and uncertainties include those
described under the captions "Item 3. Key Information - Risk
Factors" and "Item 5. Operating and Financial Review and Prospects"
in AC Immune's Annual Report on Form 20-F and other filings with
the Securities and Exchange Commission. Forward-looking statements
speak only as of the date they are made, and AC Immune does not
undertake any obligation to update them in light of new
information, future developments or otherwise, except as may be
required under applicable law. All forward-looking statements are
qualified in their entirety by this cautionary statement.
For further information, please
contact:
In EuropeDavid LoweAC Immune CorporatePhone: +41 79 281
6494E-mail: david.lowe@acimmune.com |
In the USLisa SherAC Immune Investor Relations Phone: +1 970
987 26 54E-mail: lisa.sher@acimmune.com |
Nick Miles/Toomas KullCabinet Privé de Conseils s.a.Phone: +41 22
552 46 46 E-mail: miles@cpc-pr.com
kull@cpc-pr.com |
|
AC Immune (NASDAQ:ACIU)
Historical Stock Chart
From Apr 2024 to May 2024
AC Immune (NASDAQ:ACIU)
Historical Stock Chart
From May 2023 to May 2024